Led by the UK, which piloted and launched the Subscription Model, countries around the world are changing the way they evaluate and, therefore, value antimicrobial agents.
The Subscription Model provides tariffs for guaranteed annual fees payable to the innovator of any new approved antimicrobial treatment which is made available to the National Health Service (NHS). This model recognises the value of access to a potentially life-saving treatment option, uncoupling this from the sales volume of the same agent.
Similar Pull incentives are being developed in other major jurisdictions and include:
The Pasteur Act (US): a variation on the subscription theme, the proposed bill would have the US Department of Health and Human Services grant up to $6 billion for contracts with manufacturers of new antibiotics lasting 5-10 years and ranging in value from $750 million to $3 billion; and
Transferable Exclusivity Extension Voucher (TEEV/TEV) (EU): providing innovators/manufacturers a voucher that extends market exclusivity by 12 months, applicable to another drug product in that company’s portfolio. The voucher can be sold/auctioned to third parties.
